{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:15:24Z","timestamp":1763748924117,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000723","name":"Tenovus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"Introduction<\/jats:title>Barrett\u2019s esophagus (BO) is a pre-malignant condition for esophageal adenocarcinoma (OAC), the incidence rate of which has risen dramatically over the last four decades in the Western world. The 5-year survival rate of OAC is poor, and one of the ways to improve it would be by focusing on identifying high-risk Barrett\u2019s patients through a surveillance program. Currently, histologic dysplasia is the only recognized marker of progression to OAC. Molecular biomarkers found in tissue samples that predict which patients have a higher risk of progression to OAC may act as a reliable tool for the stratification of patients with BO.<\/jats:p><\/jats:sec>Aim<\/jats:title>To determine whether molecular biomarkers have a potential use in predicting which patients with BO have a higher risk of progression to OAC.<\/jats:p><\/jats:sec>Methods<\/jats:title>Immunohistochemistry was performed on 25 tissue samples obtained from the endoscopic biopsies of 19 patients with confirmed BO. Hematoxylin and eosin (H&amp;E) staining was used to confirm the presence of BO and dysplasia. Staining was performed in an external independent laboratory. Statistical analysis using the Mann\u2013Whitney U<\/jats:italic> test was performed using R Studio\u00ae<\/jats:sup> statistical software.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 19 patients sampled, three had low-grade dysplasia (LGD), and all had confirmed metaplasia diagnostic of BO. Expression of cyclin D1 was noted to be elevated in patients with LGD compared with those with metaplasia only (p<\/jats:italic> = 0.042). Expression of Sox2 was elevated in metaplastic BO cells compared with normal squamous cells within the same stain (p = 0.046). Of all eight biomarkers tested, \u03b2-catenin had the greatest overall expression (p &lt; 0.004).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Isolating elevated cyclin D1 in patients with LGD highlights its potential use as a biomarker in identifying BO patients at risk of developing dysplasia, and, in turn, their possible progression to OAC. Elevated levels of both Sox2 and \u03b2-catenin may also serve as markers for disease progression when overexpressed in BO patients. Both conclusions, however, would need long-term follow-up to fully establish their prognostic usefulness, as at the time of writing no patients in this study had gone on to develop OAC. Although only a small sample size was present for this study, and follow-up was limited, it serves as a strong pilot for further research into the use of novel biomarkers in predicting which BO patients are at high risk of developing dysplasia and progressing to OAC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgstr.2023.1007456","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T05:01:30Z","timestamp":1684990890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular biomarkers of progression from Barrett\u2019s esophagus to esophageal adenocarcinoma"],"prefix":"10.3389","volume":"2","author":[{"given":"Luke","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani Naeem","family":"Alastal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"article-title":"Cancer research UK is a registered charity in England and Wales (1089464","volume-title":"Oesophageal cancer statistics","year":"2022","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2013-305372","article-title":"British Society of gastroenterology guidelines on the diagnosis and management of barrett\u2019s oesophagus","volume":"63","author":"Fitzgerald","year":"2014","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31819f57e9","article-title":"Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus","volume":"33","author":"Hahn","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12350","article-title":"Surveillance strategy of barrett\u2019s esophagus in the Asian region with particular reference to its locoregional epidemiology","volume":"4","author":"Di","year":"2020","journal-title":"JGH Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr203","article-title":"Risk of malignant progression in barrett\u2019s esophagus patients: results from a large population-based study","volume":"103","author":"Bhat","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300730","article-title":"The incidence of oesophageal adenocarcinoma in non-dysplastic barrett\u2019s oesophagus: a meta-analysis","volume":"61","author":"Desai","year":"2012","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02573058","article-title":"High-grade dysplasia within barrett\u2019s esophagus: controversies regarding clinical opinions and approaches","volume":"9","author":"Al-Kasspooles","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","article-title":"ACG clinical guideline: diagnosis and management of barrett\u2019s esophagus","volume":"111","author":"Shaheen","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0685-1","article-title":"Novel biomarkers for risk stratification of barrett\u2019s oesophagus associated neoplastic progression\u2013epithelial HMGB1 expression and stromal lymphocytic phenotype","volume":"122","author":"Porter","year":"2020","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds181","article-title":"The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends","volume":"23","author":"Thrift","year":"2012","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0012","article-title":"Esophageal adenocarcinoma incidence: are we reaching the peak","volume":"19","author":"Pohl","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001105","article-title":"Cost-effectiveness analysis on endoscopic surveillance among Western patients with barrett\u2019s esophagus for esophageal adenocarcinoma screening","volume":"94","author":"Yang","year":"2015","journal-title":"Medicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-012-1949-8","article-title":"Overview of personalized medicine in GI cancers","volume":"16","author":"Chao","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s10620-018-5088-2","article-title":"Biomarkers of barrett\u2019s esophagus: from the laboratory to clinical practice","volume":"63","author":"Konda","year":"2018","journal-title":"Dig Dis Sci"},{"volume-title":"Biomarkers of progression from barrett\u2019s oesophagus to oesophageal adenocarcinoma","year":"2019","author":"Alastal","key":"B15"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.152","article-title":"The presence of genetic mutations at key loci predicts progression to esophageal adenocarcinoma in barrett\u2019s esophagus","volume":"110","author":"Eluri","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1385","article-title":"Cyclin a immunocytology as a risk stratification tool for barrett\u2019s esophagus surveillance","volume":"13","author":"Lao-Sirieix","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.260","article-title":"SOX2 as a novel marker to predict neoplastic progression in barrett\u2019s esophagus","volume":"110","author":"van Olphen","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.gastro.2012.06.041","article-title":"Population-based study reveals new risk-stratification biomarker panel for barrett\u2019s esophagus","volume":"143","author":"Bird-Lieberman","year":"2012","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.437","article-title":"Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in barrett\u2019s esophagus: a case-control study","volume":"104","author":"Sikkema","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-1164","article-title":"A tissue systems pathology assay for high-risk barrett\u2019s esophagus","volume":"25","author":"Critchley-Thorne","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ng1768","article-title":"Genetic clonal diversity predicts progression to esophageal adenocarcinoma","volume":"38","author":"Maley","year":"2006","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41389-020-00266-y","article-title":"The membrane-associated form of cyclin D1 enhances cellular invasion","volume":"9","author":"Chen","year":"2020","journal-title":"Oncogenesis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4294-5","article-title":"High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers","volume":"164","author":"Ahlin","year":"2017","journal-title":"Breast Cancer Res Treat"},{"volume-title":"Methods in observational epidemiology","year":"1996","author":"Kelsey","key":"B25"},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2559.2009.03288.x","article-title":"Barrett\u2019s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry","volume":"54","author":"Kaye","year":"2009","journal-title":"Histopathology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.450","article-title":"Biomarkers of barrett\u2019s esophagus","volume":"5","author":"Fouad","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.2","article-title":"Predictors of progression in barrett\u2019s esophagus: current knowledge and future directions","volume":"105","author":"Prasad","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103042","article-title":"Incidence of adenocarcinoma among patients with barrett\u2019s esophagus","volume":"365","author":"Hvid-Jensen","year":"2011","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.31","article-title":"Esophageal adenocarcinoma in barrett\u2019s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review","volume":"104","author":"Wani","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrc2773","article-title":"Barrett\u2019s oesophagus and oesophageal adenocarcinoma: time for a new synthesis","volume":"10","author":"Reid","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040067","article-title":"NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma","volume":"4","author":"Galipeau","year":"2007","journal-title":"PloS Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.05261.x","article-title":"Predictors of progression in barrett\u2019s esophagus III: baseline flow cytometric variables","volume":"96","author":"Rabinovitch","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.16.1316","article-title":"Prospective study of cyclin D1 overexpression in barrett\u2019s esophagus: association with increased risk of adenocarcinoma","volume":"92","author":"Bani-Hani","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e318168598b","article-title":"p16, cyclin D1, ki-67, and AMACR as markers for dysplasia in Barrett esophagus","volume":"16","author":"Shi","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03851.x","article-title":"p53 protein overexpression in low grade dysplasia (LGD) in barrett\u2019s esophagus: immunohistochemical marker predictive of progression","volume":"96","author":"Weston","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310126","article-title":"A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early barrett\u2019s neoplasia","volume":"66","author":"Terheggen","year":"2017","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"Alao","year":"2007","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.034298","article-title":"Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study","volume":"59","author":"Langer","year":"2006","journal-title":"J Clin Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO.2006.08.0283","article-title":"Cyclin D1 guanine\/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma","volume":"25","author":"Izzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15687","article-title":"The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities","volume":"8","author":"Shang","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-020-00242-3","article-title":"Functional characterization of SOX2 as an anticancer target","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"17639","DOI":"10.1038\/s41598-018-36251-0","article-title":"Sox2 is associated with cancer stem-like properties in colorectal cancer","volume":"8","author":"Takeda","year":"2018","journal-title":"Sci Rep"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2023.1007456\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T05:01:33Z","timestamp":1684990893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2023.1007456\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":43,"alternative-id":["10.3389\/fgstr.2023.1007456"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2023.1007456","relation":{},"ISSN":["2813-1169"],"issn-type":[{"type":"electronic","value":"2813-1169"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1007456"}}